SNX17: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders
SNX17: A Potential Drug Target for Cancer, Neurodegenerative Diseases and Autoimmune Disorders
SNX17 (KIAA0064) is a protein that is expressed in various tissues of the body, including the brain, heart, and kidneys. It is a member of the superfamily of RNA-binding proteins known as scaffold proteins, and it has been shown to play a role in the regulation of cellular processes such as cell adhesion, migration, and survival.
Recent studies have suggested that SNX17 may be a drug target (or biomarker) for the treatment of various diseases, including cancer, neurodegenerative diseases, and autoimmune disorders. This is because SNX17 has been shown to interact with a variety of molecules, including transcription factors , cytokines, and proteins involved in signaling pathways that are involved in the development and progression of these diseases.
One of the potential mechanisms by which SNX17 may be involved in the development and progression of cancer is its role in cell adhesion and migration. Studies have shown that SNX17 is involved in the regulation of cell-cell adhesion by interacting with proteins such as E-cadherin , which is a protein that is involved in the formation of tight junctions that help to maintain tissue structure and prevent the passage of harmful substances into the body.
In addition, SNX17 has also been shown to be involved in the regulation of cell migration, which is the process by which cells move from their place of origin to their destination in the body. Studies have shown that SNX17 plays a role in the migration of cancer cells to new tumors, which could make it an attractive target for cancer therapies.
Another potential mechanism by which SNX17 may be involved in the development and progression of neurodegenerative diseases is its role in the regulation of cellular signaling pathways that are involved in the development and progression of these diseases. For example, SNX17 has been shown to interact with the protein TrkB, which is involved in the regulation of neurotransmitter release and the maintenance of cellular signaling pathways.
In addition, SNX17 has also been shown to be involved in the regulation of cellular processes that are involved in the development and progression of neurodegenerative diseases, such as the regulation of neurotransmitter synthesis and the maintenance of cellular signaling pathways.
Finally, SNX17 may also be an attractive target for the treatment of autoimmune disorders because it has been shown to play a role in the regulation of cellular signaling pathways that are involved in the development and progression of these disorders. For example, SNX17 has been shown to interact with the protein Fc蔚RI, which is involved in the regulation of immune responses and the development of autoimmune diseases.
In conclusion, SNX17 is a protein that has been shown to play a role in a variety of cellular processes that are involved in the development and progression of various diseases. As such, it may be an attractive target for the development of new therapies for these diseases. Further research is needed to fully understand the role of SNX17 in the regulation of cellular processes and to determine its potential as a drug target or biomarker.
Protein Name: Sorting Nexin 17
Functions: Critical regulator of endosomal recycling of numerous surface proteins, including integrins, signaling receptor and channels (PubMed:15121882, PubMed:15769472). Binds to NPxY sequences in the cytoplasmic tails of target cargos (PubMed:21512128). Associates with retriever and CCC complexes to prevent lysosomal degradation and promote cell surface recycling of numerous cargos such as integrins ITGB1, ITGB5 and their associated alpha subunits (PubMed:28892079, PubMed:22492727). Also required for maintenance of normal cell surface levels of APP and LRP1 (PubMed:16712798, PubMed:19005208). Interacts with membranes containing phosphatidylinositol 3-phosphate (PtdIns(3P)) (PubMed:16712798)
The "SNX17 Target / Biomarker Review Report" is a customizable review of hundreds up to thousends of related scientific research literature by AI technology, covering specific information about SNX17 comprehensively, including but not limited to:
• general information;
• protein structure and compound binding;
• protein biological mechanisms;
• its importance;
• the target screening and validation;
• expression level;
• disease relevance;
• drug resistance;
• related combination drugs;
• pharmacochemistry experiments;
• related patent analysis;
• advantages and risks of development, etc.
The report is helpful for project application, drug molecule design, research progress updates, publication of research papers, patent applications, etc. If you are interested to get a full version of this report, please feel free to contact us at BD@silexon.ai
More Common Targets
SNX18 | SNX18P23 | SNX18P24 | SNX18P3 | SNX19 | SNX2 | SNX20 | SNX21 | SNX22 | SNX24 | SNX25 | SNX27 | SNX29 | SNX29P1 | SNX29P2 | SNX3 | SNX30 | SNX31 | SNX32 | SNX33 | SNX4 | SNX5 | SNX6 | SNX7 | SNX8 | SNX9 | SOAT1 | SOAT2 | SOBP | SOCAR | SOCS1 | SOCS2 | SOCS2-AS1 | SOCS3 | SOCS3-DT | SOCS4 | SOCS5 | SOCS5P5 | SOCS6 | SOCS7 | SOD1 | SOD2 | SOD2-OT1 | SOD3 | Sodium channel | Sodium-Glucose Cotransporter (SGLT) | Sodium-potassium-calcium exchanger | SOGA1 | SOGA3 | SOHLH1 | SOHLH2 | Soluble (cytosolic) protein tyrosine phosphatases | Soluble guanylyl cyclase | Solute Carrier Family 12 | Solute carrier family 29 member | Somatostatin receptor | SON | SORBS1 | SORBS2 | SORBS3 | SORCS1 | SORCS2 | SORCS3 | SORCS3-AS1 | SORD | SORD2P | SORL1 | SORT1 | Sorting and assembly machinery complex | Sorting nexin | SOS1 | SOS2 | SOSS complex | SOST | SOSTDC1 | SOWAHA | SOWAHB | SOWAHC | SOWAHD | SOX1 | SOX1-OT | SOX10 | SOX11 | SOX12 | SOX13 | SOX14 | SOX15 | SOX17 | SOX18 | SOX2 | SOX2-OT | SOX21 | SOX21-AS1 | SOX3 | SOX30 | SOX30P1 | SOX4 | SOX5 | SOX5-AS1 | SOX6
